ペンシルベニアにおける卵巣がんの臨床試験
ペンシルベニア内の拠点で、卵巣がんに関する69件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- 他18件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- IRMC Cancer Center, Indiana
- UPMC Hillman Cancer Center - New Castle, New Castle
- 他2件
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0232 - University of Pennsylvania, Philadelphia
- Site 0178 - Thomas Jefferson University, Philadelphia
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT05128825Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- University of Pennsylvania, Philadelphia
被験者募集中
18歳以上 · 女性 · 2026/09/29更新 · NCT05287451A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- St. Lukes University Hospital /ID# 274362, Bethlehem
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/24更新 · NCT04590326Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Penn Medicine University of Pennsylvania Health System /ID# 277963, Philadelphia
- Western Pennsylvania Gynecologic Oncology /ID# 278632, Pittsburgh
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Pennsylvania Hospital, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791Prehabilitation in High-risk Oncologic Surgery
- Fox Chase Cancer Center - Philadelphia, Philadelphia
被験者募集中
18歳以上 · 全性別 · 2026/09/21更新 · NCT07638410BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- University of Pennsylvania, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT04752826A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Hospital of the University of Pennsylvania ( Site 0071), Philadelphia
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Penn State College of Medicine, Hershey
被験者募集中第2相
18歳〜99歳 · 女性 · 2026/09/15更新 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh
- Allegheny Health Network- West Penn Hospital, Pittsburgh
- Lankenau Medical Center, Wynnewood
- 他1件
被験者募集中第3相
18歳以上 · 女性 · 2026/09/15更新 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Allegheny Singer, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06303505Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- St. Luke's University Health Network, Bethlehem
被験者募集中第3相
18歳以上 · 女性 · 2026/09/14更新 · NCT04575935Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh
- West Penn Hospital of Allegheny Health Network, Pittsburgh
被験者募集中第2相
18歳以上 · 女性 · 2026/09/14更新 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Allegheny Health Network West Penn Hospital ( Site 0099), Pittsburgh
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06824467FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07216105Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- AHN West Penn Hospital, Pittsburgh
被験者募集中第3相
18歳以上 · 女性 · 2026/08/26更新 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1相
15歳以上 · 全性別 · 2026/08/25更新 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06774963Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07001748A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07470853The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
- ACPMP, Springfield
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/17更新 · NCT07769346A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0109, Philadelphia
- Site 0113, Philadelphia
- Site 0114, Willow Grove
被験者募集中第3相
18歳以上 · 女性 · 2026/08/12更新 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Jefferson Abington Hospital, Abington
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Penn State Milton S Hershey Medical Center, Hershey
- 他15件
被験者募集中
35歳〜50歳 · 女性 · 2026/08/07更新 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Saint Luke's Cancer Center - Allentown, Allentown
- Saint Luke's University Hospital-Bethlehem Campus, Bethlehem
- 他21件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。